11. Microvascular complications and foot care: Standards of Medical Care in Diabete-2020

Diabetes Care

Volumn 43, Issue , 2020, Pages S135-S151

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEVACIZUMAB; CANAGLIFLOZIN; CARBAMAZEPINE; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOMPERIDONE; DULOXETINE; EMPAGLIFLOZIN; ERYTHROMYCIN; GABAPENTIN; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GUANFACINE; LIRAGLUTIDE; METFORMIN; METOCLOPRAMIDE; MINERALOCORTICOID ANTAGONIST; PLACEBO; PREGABALIN; PROSTAGLANDIN; RANIBIZUMAB; SEMAGLUTIDE; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; TAPENTADOL; UNINDEXED DRUG; VASCULOTROPIN INHIBITOR; VENLAFAXINE;

ACUTE KIDNEY FAILURE; AKATHISIA; ALBUMINURIA; ARTICLE; AUTONOMIC NEUROPATHY; CARDIAC AUTONOMIC NEUROPATHY; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; DIABETES MELLITUS; DIABETIC FOOT; DIABETIC MACULAR EDEMA; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DRUG DOSE TITRATION; DRUG WITHDRAWAL; DYSTONIA; END STAGE RENAL DISEASE; ERECTILE DYSFUNCTION; ESTIMATED GLOMERULAR FILTRATION RATE; EXTRAPYRAMIDAL SYMPTOM; GASTROINTESTINAL MOTILITY DISORDER; GLYCEMIC CONTROL; HUMAN; HYPERBARIC OXYGEN THERAPY; HYPERKALEMIA; HYPERTENSION; HYPOGLYCEMIA; HYPOKALEMIA; INSULIN DEPENDENT DIABETES MELLITUS; LASER COAGULATION; MALNUTRITION; NEPHROLOGIST; NEUROPATHIC PAIN; NON INSULIN DEPENDENT DIABETES MELLITUS; OPTIMAL DRUG DOSE; ORTHOSTATIC HYPOTENSION; PARKINSONISM; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT REFERRAL; PERIPHERAL OCCLUSIVE ARTERY DISEASE; POTASSIUM RESTRICTION; PROLIFERATIVE DIABETIC RETINOPATHY; RESISTANT HYPERTENSION; SCREENING; SODIUM RESTRICTION; STOMACH PARESIS; TARDIVE DYSKINESIA; UNSPECIFIED SIDE EFFECT; DIABETIC ANGIOPATHY; ENDOCRINOLOGY; HEALTH CARE QUALITY; HISTORY; MEDICAL SOCIETY; ORGANIZATION AND MANAGEMENT; PRACTICE GUIDELINE; PROCEDURES; STANDARD; UNITED STATES;

DIABETES MELLITUS; DIABETIC ANGIOPATHIES; DIABETIC FOOT; ENDOCRINOLOGY; HISTORY, 21ST CENTURY; HUMANS; REFERENCE STANDARDS; SOCIETIES, MEDICAL; STANDARD OF CARE; UNITED STATES;

EID: 85077091003     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc20-S011     Document Type: Article

References (188)

1. Tuttle KR, Bakris GL, Bilous RW, et al. Diabetic kidney disease: A report from an ADA Consensus Conference. Diabetes Care 2014; 37:2864-2883
2. National Kidney Foundation. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013; 3:1-150
3. Afkarian M, Zelnick LR, Hall YN, et al. Clinical manifestations of kidney disease among US Adults with diabetes, 1988-2014. JAMA 2016; 316:602-610
4. de Boer IH, Rue TC, Hall YN, Heagerty PJ, Weiss NS, Himmelfarb J. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA 2011; 305:2532-2539
5. de Boer IH; DCCT/EDIC Research Group. Kidney disease and related findings in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study. Diabetes Care 2014; 37:24-30
6. United States Renal Data System. Annual Data Report: Epidemiology of Kidney Disease in the United STates. Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2016
7. Fox CS, Matsushita K, Woodward M, et al.; Chronic Kidney Disease Prognosis Consortium. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: A metaanalysis. Lancet 2012; 380:1662-1673
8. Afkarian M, Sachs MC, Kestenbaum B, et al. Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol 2013; 24:302-308
9. Groop P-H, Thomas MC, Moran JL, et al.; FinnDiane Study Group. The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes. Diabetes 2009; 58: 1651-1658
10. Gomes MB, Gonçalves MF. Is there a physiological variability for albumin excretion rate? Study in patients with diabetes type 1 and nondiabetic individuals. Clin Chim Acta 2001; 304: 117-123
11. Naresh CN, Hayen A, Weening A, Craig JC, Chadban SJ. Day-to-day variability in spot urine albumin-creatinine ratio. Am J Kidney Dis 2013; 62:1095-1101
12. Tankeu AT, Kaze FF, Noubiap JJ, Chelo D, Dehayem MY, Sobngwi E. Exercise-induced albuminuria and circadian blood pressure abnormalities intype2diabetes. WorldJNephrol2017; 6:209-216
13. Delanaye P, Glassock RJ, Pottel H, Rule AD. An age-calibrated definition of chronic kidney disease: Rationale and benefits. Clin Biochem Rev 2016; 37:17-26
14. Kramer HJ, Nguyen QD, Curhan G, Hsu C-Y. Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA 2003; 289:3273-3277
15. Molitch ME, Steffes M, Sun W, et al.; Epidemiology of Diabetes Interventions and Complications Study Group. Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the Diabetes Control and Complications Trial and the Epidemiology of Diabetes Interventions and Complications study. Diabetes Care 2010; 33: 1536-1543
16. He F, Xia X, Wu XF, Yu XQ, Huang FX. Diabetic retinopathy in predicting diabetic nephropathy in patients with type 2 diabetes and renal disease: A meta-analysis. Diabetologia 2013; 56:457-466
17. Levey AS, Coresh J, Balk E, et al.; National Kidney Foundation. National Kidney Foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Ann Intern Med 2003; 139:137-147
18. Flynn C, Bakris GL. Noninsulin glucoselowering agents for the treatment of patients on dialysis. Nat Rev Nephrol 2013; 9:147-153
19. Matzke GR, Aronoff GR, Atkinson AJ Jr, et al. Drug dosing consideration in patients with acute and chronic kidney disease-a clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2011; 80:1122-1137
20. Coresh J, Turin TC, Matsushita K, et al. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. JAMA 2014; 311:2518-2531
21. Zhou J, Liu Y, Tang Y, et al. A comparison of RIFLE, AKIN, KDIGO, and Cys-C criteria for the definition of acute kidney injury in critically ill patients. Int Urol Nephrol 2016; 48:125-132
22. Hoste EAJ, Kellum JA, Selby NM, et al. Global epidemiology and outcomes of acute kidney injury. Nat Rev Nephrol 2018; 14:607-625
23. JamesMT, GramsME, Woodward M, et al.; CKD Prognosis Consortium. A meta-analysis of the association of estimated GFR, albuminuria, diabetes mellitus, and hypertension with acute kidney injury. Am J Kidney Dis 2015; 66:602-612
24. Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019; 380:2295-2306
25. Nadkarni GN, Ferrandino R, Chang A, et al. Acute kidney injury in patients on SGLT2 inhibitors: A propensity-matched analysis. Diabetes Care 2017; 40:1479-1485
26. Wanner C, Inzucchi SE, Lachin JM, et al.; EMPA-REG OUTCOME Investigators. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016; 375:323-334
27. Neuen BL, Ohkuma T, Neal B, et al. Cardiovascular and renal outcomes with canagliflozin according to baseline kidney function: Data from the CANVAS Program. Circulation 2018; 138: 1537-1550
28. Thakar CV, Christianson A, Himmelfarb J, Leonard AC. Acute kidney injury episodes and chronic kidney disease risk in diabetes mellitus. Clin J Am Soc Nephrol 2011; 6:2567-2572
29. Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: Is this a cause for concern? Arch Intern Med 2000; 160:685-693
30. Beddhu S, Greene T, Boucher R, et al. Intensive systolic blood pressure control and incident chronic kidney disease in people with and without diabetes mellitus: Secondary analyses of two randomised controlled trials. Lancet Diabetes Endocrinol 2018; 6:555-563
31. Collard D, Brouwer TF, Peters RJG, Vogt L, van den Born BH. Creatinine rise during blood pressure therapy and the risk of adverse clinical outcomes in patients with type 2 diabetes mellitus. Hypertension 2018; 72:1337-1344
32. Malhotra R, Craven T, Ambrosius WT, et al.; SPRINT Research Group. Effects of intensive blood pressure lowering on kidney tubule injury in CKD: A longitudinal subgroup analysis in SPRINT. Am J Kidney Dis 2019; 73:21-30
33. Hughes-Austin JM, Rifkin DE, Beben T, et al. The relation of serum potassium concentration with cardiovascular events and mortality in community-living individuals. Clin J Am Soc Nephrol 2017; 12:245-252
34. Bandak G, Sang Y, Gasparini A, et al. Hyperkalemia after initiating renin-angiotensin system blockade: The Stockholm Creatinine Measurements (SCREAM) project. J AmHeart Assoc 2017; 6:e005428
35. Nilsson E, Gasparini A, Ärnlöv J, et al. Incidence and determinants of hyperkalemia and hypokalemia in a large healthcare system. Int J Cardiol 2017; 245:277-284
36. de Boer IH, Gao X, Cleary PA, et al.; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group. Albuminuria changes and cardiovascular and renal outcomes in type1 diabetes: The DCCT/EDICstudy. Clin JAm Soc Nephrol 2016; 11:1969-1977
37. Sumida K, Molnar MZ, Potukuchi PK, et al. Changes in albuminuria and subsequent risk of incident kidney disease. Clin J Am Soc Nephrol 2017; 12:1941-1949
38. Inker LA, Grams ME, Levey AS, et al.; CKD Prognosis Consortium. Relationship of estimated GFR and albuminuria to concurrent laboratory abnormalities: An individual participant data meta-analysis in a global consortium. Am J Kidney Dis 2019; 73:206-217
39. Klahr S, Levey AS, Beck GJ, et al.; Modification of Diet in Renal Disease Study Group. The effects of dietary protein restriction and bloodpressure control on the progression of chronic renal disease. N Engl J Med 1994; 330:877-884
40. Mills KT, Chen J, Yang W, et al.; Chronic Renal Insufficiency Cohort (CRIC) Study Investigators. Sodium excretion and the risk of cardiovascular disease in patients with chronic kidney disease. jama 2016; 315:2200-2210
41. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 2018; 71:1269-1324
42. Murray DP, Young L, Waller J, et al. Is dietary protein intake predictive of 1-year mortality in dialysis patients? Am J Med Sci 2018; 356:234-243
43. DCCT/EDIC research group. Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: Long-term follow-up of the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications study. Lancet Diabetes Endocrinol 2014; 2:793-800
44. de Boer IH, Sun W, Cleary PA, et al.; DCCT/EDIC Research Group. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med 2011; 365:2366-2376
45. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352:854-865
46. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352:837-853
47. Patel A, MacMahon S, Chalmers J, et al.; ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358:2560-2572
48. Ismail-Beigi F, Craven T, Banerji MA, et al.; ACCORD trial group. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: An analysis of the ACCORDrandomised trial. Lancet 2010; 376:419-430
49. Zoungas S, Chalmers J, Neal B, et al.; ADVANCE-ON Collaborative Group. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med 2014; 371:1392-1406
50. Zoungas S, Arima H, Gerstein HC, et al.; Collaborators on Trials of Lowering Glucose (CONTROL) group. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: A meta-analysis of individual participant data from randomised controlled trials. Lancet Diabetes Endocrinol 2017; 5:431-437
51. Agrawal L, Azad N, Bahn GD, et al.; VADT Study Group. Long-term follow-up of intensive glycaemic control on renal outcomes in the Veterans Affairs Diabetes Trial (VADT). Diabetologia 2018; 61:295-299
52. Miller ME, Bonds DE, Gerstein HC, et al.; ACCORD Investigators. The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: Post hoc epidemiological analysis of the ACCORD study. BMJ 2010; 340:b5444
53. Papademetriou V, Lovato L, Doumas M, et al.; ACCORD Study Group. Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes. Kidney Int 2015; 87:649-659
54. Perkovic V, Heerspink HL, Chalmers J, et al.; ADVANCECollaborative Group. Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney Int 2013; 83:517-523
55. Wong MG, Perkovic V, Chalmers J, et al.; ADVANCE-ON Collaborative Group. Long-term benefits of intensive glucose control for preventing end-stage kidney disease: ADVANCE-ON. Diabetes Care 2016; 39:694-700
56. National Kidney Foundation. KDOQI clinical practice guideline for diabetesandCKD: 2012Update. Am J Kidney Dis 2012; 60:850-886
57. Cherney DZI, Perkins BA, Soleymanlou N, et al. Renal hemodynamic effect of sodiumglucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 2014; 129:587-597
58. Heerspink HJL, Desai M, Jardine M, Balis D, Meininger G, Perkovic V. Canagliflozin slows progression of renal function decline independently of glycemic effects. J Am Soc Nephrol 2017; 28:368-375
59. Neal B, Perkovic V, Mahaffey KW, et al.; CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377:644-657
60. Zelniker TA, Braunwald E. Cardiac and renal effects of sodium-glucose co-transporter 2 inhibitors in diabetes: JACC state-of-the-art review. J Am Coll Cardiol 2018; 72:1845-1855
61. Woods TC, Satou R, Miyata K, et al. Canagliflozin prevents intrarenal angiotensinogen augmentation and mitigates kidney injury and hypertension in mouse model of type 2 diabetes mellitus. Am J Nephrol 2019; 49:331-342
62. Heerspink HJL, Perco P, Mulder S, et al. Canagliflozin reduces inflammation and fibrosis biomarkers: A potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease. Diabetologia 2019; 62:1154-1166
63. Yaribeygi H, Butler AE, Atkin SL, Katsiki N, Sahebkar A. Sodium-glucose cotransporter 2 inhibitors and inflammation in chronic kidney disease: Possible molecular pathways. J Cell Physiol 2018; 234:223-230
64. Marso SP, Daniels GH, Brown-Frandsen K, et al.; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 375: 311-322
65. Cooper ME, Perkovic V, McGill JB, et al. Kidney disease end points in a pooled analysis of individual patient-level data from a large clinical trials program of the dipeptidyl peptidase 4 inhibitor linagliptin in type 2 diabetes. Am J Kidney Dis 2015; 66:441-449
66. Mann JFE, Ørsted DD, Brown-Frandsen K, et al.; LEADER Steering Committee and Investigators. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med 2017; 377:839-848
67. Marso SP, Bain SC, Consoli A, et al.; SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. NEngl J Med 2016; 375:1834-1844
68. Karter AJ, Warton EM, Lipska KJ, et al. Development and validation of a tool to identify patients with type 2 diabetes at high risk of hypoglycemia-related emergency department or hospital use. JAMA Intern Med 2017; 177:1461-1470
69. Moen MF, Zhan M, Hsu VD, et al. Frequency of hypoglycemia and its significance in chronic kidney disease. Clin J Am Soc Nephrol 2009; 4: 1121-1127
70. U.S. Food and Drug Administration. FDA drug safety communication: FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function, 2016. Accessed 4 November 2019. Available from http://www.fda.gov/Drugs/DrugSafety/ucm493244.htm
71. Zinman B, WannerC, Lachin JM, et al.; EMPAREG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373:2117-2128
72. Mahaffey KW, Neal B, Perkovic V, et al.; CANVAS Program Collaborative Group. Canagliflozin for primary and secondary prevention of cardiovascular events: Results from the CANVAS program (Canagliflozin Cardiovascular Assessment Study). Circulation 2018; 137:323-334
73. Jardine MJ, Mahaffey KW, Neal B, et al.; CREDENCE study investigators. The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) study rationale, design, and baseline characteristics. Am J Nephrol 2017; 46:462-472
74. Mahaffey KW, Jardine MJ, Bompoint S, et al. Canagliflozin and cardiovascular and renal outcomes in type 2 diabetes mellitus and chronic kidney disease in primary and secondary cardiovascular prevention groups. Circulation 2019; 140:739-750
75. Bakris GL. Major advancements in slowing diabetic kidney disease progression: Focus on SGLT2 inhibitors. Am J Kidney Dis. 28 June 2019 [Epub ahead of print]. DOI: 10.1053/j.ajkd.2019.05.009
76. Novo Nordisk A/S. A research study to see how semaglutide works compared to placebo in people with type 2 diabetes and chronic kidney disease (FLOW). In: ClinicalTrials.gov. Bethesda, MD, National Library of Medicine, 2019. Accessed 11 September 2019. Available from https://clinicaltrials.gov/ct2/show/NCT03819153
77. Franki, L. FDA approves label extension for dapagliflozin. Accessed 11 September 2019. Available from https://www.mdedge.com/endocrinology/article/195314/diabetes/fda-approves-label-extension-dapagliflozin
78. Leehey DJ, Zhang JH, Emanuele NV, et al.; VA NEPHRON-D Study Group. BP and renal outcomes in diabetic kidney disease: The Veterans Affairs Nephropathy in Diabetes Trial. Clin J Am Soc Nephrol 2015; 10:2159-2169
79. Emdin CA, Rahimi K, Neal B, Callender T, Perkovic V, Patel A. Blood pressure lowering in type 2 diabetes: A systematic review and metaanalysis. JAMA 2015; 313:603-615
80. Cushman WC, Evans GW, Byington RP, et al.; ACCORD Study Group. Effects of intensive bloodpressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362:1575-1585
81. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317:703-713
82. de Boer IH, Bangalore S, Benetos A, et al. Diabetes and hypertension: A position statement by the American Diabetes Association. Diabetes Care 2017; 40:1273-1284
83. Brenner BM, Cooper ME, de Zeeuw D, et al.; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861-869
84. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD; The Collaborative Study Group. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456-1462
85. Lewis EJ, Hunsicker LG, Clarke WR, et al.; Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:851-860
86. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355:253-259
87. Barnett AH, Bain SC, Bouter P, et al.; Diabetics Exposed to Telmisartan and Enalapril Study Group. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004; 351:1952-1961
88. Wu H-Y, Peng C-L, Chen P-C, et al. Comparative effectiveness of angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers for major renal outcomes in patients with diabetes: A 15-year cohort study. PLoS One 2017; 12:e0177654
89. Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345:870-878
90. Mauer M, Zinman B, Gardiner R, et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 2009; 361:40-51
91. Weil EJ, Fufaa G, Jones LI, et al. Effect of losartan on prevention and progression of early diabetic nephropathy in American Indians with type 2 diabetes. Diabetes 2013; 62:3224-3231
92. Bangalore S, Fakheri R, Toklu B, Messerli FH. Diabetes mellitus as a compelling indication for use of renin angiotensin system blockers: Systematic review and meta-analysis of randomized trials. BMJ 2016; 352:i438
93. Haller H, Ito S, Izzo JL Jr, et al.; ROADMAPTrial Investigators. Olmesartan for the delay or prevention of microalbuminuria in type2 diabetes. N Engl J Med 2011; 364:907-917
94. Yusuf S, Teo KK, Pogue J, et al.; ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358:1547-1559
95. Fried LF, Emanuele N, Zhang JH, et al.; VA NEPHRON-D Investigators. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 2013; 369:1892-1903
96. Bakris GL, Agarwal R, Chan JC, et al.; Mineralocorticoid Receptor Antagonist Tolerability Study-Diabetic Nephropathy (ARTS-DN) Study Group. Effect of finerenone on albuminuria in patients with diabetic nephropathy: A randomized clinical trial. JAMA 2015; 314:884-894
97. Williams B, MacDonald TM, Morant S, et al.; British Hypertension Society's PATHWAY Studies Group. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): A randomised, double-blind, crossover trial. Lancet 2015; 386:2059-2068
98. Filippatos G, Anker SD, Böhm M, et al. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetesmellitus and/or chronic kidney disease. Eur Heart J 2016; 37:2105-2114
99. Smart NA, Dieberg G, Ladhani M, Titus T. Early referral to specialist nephrology services for preventing the progression to end-stage kidney disease. Cochrane Database Syst Rev 2014; 6: CD007333
100. Solomon SD, Chew E, Duh EJ, et al. Diabetic retinopathy: A position statement by the American Diabetes Association. Diabetes Care 2017; 40:412-418
101. Klein R. Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care 1995; 18:258-268
102. Estacio RO, McFarling E, Biggerstaff S, Jeffers BW, Johnson D, Schrier RW. Overt albuminuria predicts diabetic retinopathy in Hispanics with NIDDM. Am J Kidney Dis 1998; 31: 947-953
103. Leske MC, Wu S-Y, Hennis A, et al.; Barbados Eye Study Group. Hyperglycemia, blood pressure, and the 9-year incidence of diabetic retinopathy: The Barbados Eye Studies. Ophthalmology 2005; 112:799-805
104. Chew EY, Davis MD, Danis RP, et al.; Action to Control Cardiovascular Risk in Diabetes Eye Study Research Group. The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: The Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study. Ophthalmology 2014; 121:2443-2451
105. Nathan DM, Genuth S, Lachin J, et al.; Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329:977-986
106. Chew EY, Ambrosius WT, Davis MD, et al.; ACCORD Study Group; ACCORD Eye Study Group. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010; 363:233-244
107. Gubitosi-Klug RA, Sun W, Cleary PA, et al.; Writing Team for the DCCT/EDIC Research Group. Effects of prior intensive insulin therapy and risk factors on patient-reported visual function outcomes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) cohort. JAMA Ophthalmol 2016; 134: 137-145
108. Fong DS, Aiello LP, Ferris FL 3rd, Klein R. Diabetic retinopathy. Diabetes Care 2004; 27: 2540-2553
109. Diabetes Control and Complications Trial Research Group. Effect of pregnancy on microvascular complications in the Diabetes Control and Complications Trial. Diabetes Care 2000; 23: 1084-1091
110. Dabelea D, Stafford JM, Mayer-Davis EJ, et al.; SEARCH for Diabetes in Youth Research Group. Association of type 1 diabetes vs type 2 diabetes diagnosed during childhood and adolescence with complications during teenage years and young adulthood. JAMA 2017; 317: 825-835
111. Agardh E, Tababat-Khani P. Adopting 3-year screening intervals for sight-threatening retinal vascular lesions in type 2 diabetic subjects without retinopathy. Diabetes Care 2011; 34:1318-1319
112. Nathan DM, Bebu I, Hainsworth D, et al.; DCCT/EDIC Research Group. Frequency of evidence-based screening for retinopathy in type 1 diabetes. N Engl J Med 2017; 376: 1507-1516
113. Daskivich LP, Vasquez C, Martinez C Jr, Tseng C-H, Mangione CM. Implementation and evaluation of a large-scale teleretinal diabetic retinopathy screening program in the Los Angeles County Department of Health Services. JAMA Intern Med 2017; 177:642-649
114. Sim DA, Mitry D, Alexander P, et al. The evolution of teleophthalmology programs in the United Kingdom: Beyond diabetic retinopathy screening. J Diabetes Sci Technol 2016; 10: 308-317
115. Abràmoff MD, Lavin PT, Birch M, Shah N, Folk JC. Pivotal trial of an autonomous AI-based diagnostic system for detection of diabetic retinopathy in primary care offices. NPJ Digit Med 2018; 1:39
116. Hooper P, Boucher MC, Cruess A, et al. Canadian Ophthalmological Society evidencebased clinical practice guidelines for the management of diabetic retinopathy. Can J Ophthalmol 2012; 47(Supp. 1):S1-S30
117. Axer-Siegel R, Hod M, Fink-Cohen S, et al. Diabetic retinopathy during pregnancy. Ophthalmology 1996; 103:1815-1819
118. Best RM, Chakravarthy U. Diabetic retinopathy in pregnancy. Br J Ophthalmol 1997; 81:249-251
119. Gunderson EP, Lewis CE, Tsai A-L, et al. A 20-year prospective study of childbearing and incidence of diabetes in young women, controlling for glycemia before conception: The Coronary Artery Risk Development in Young Adults (CARDIA) Study. Diabetes 2007; 56: 2990-2996
120. The Diabetic Retinopathy Study Research Group. Preliminary report on effects of photocoagulation therapy. Am J Ophthalmol 1976; 81: 383-396
121. Gross JG, Glassman AR, Jampol LM, et al.; Writing Committee for the Diabetic Retinopathy Clinical Research Network. Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: A randomized clinical trial. JAMA 2015; 314:2137-2146
122. Early Treatment Diabetic Retinopathy Study research group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 1985; 103:1796-1806
123. Elman MJ, Bressler NM, Qin H, et al.; Diabetic Retinopathy Clinical Research Network. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2011; 118:609-614
124. Mitchell P, Bandello F, Schmidt-Erfurth U, et al.; RESTORE study group. The RESTORE study: Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011; 118: 615-625
125. Nguyen QD, Brown DM, Marcus DM, et al.; RISE and RIDE Research Group. Ranibizumab for diabetic macular edema: Results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 2012; 119:789-801
126. Shih C-J, Chen H-T, Kuo S-C, et al. Comparative effectiveness of angiotensin-convertingenzyme inhibitors and angiotensin II receptor blockers in patients with type 2 diabetes and retinopathy. CMAJ 2016; 188:E148-E157
127. Shi R, Zhao L, Wang F, et al. Effects of lipidlowering agents on diabetic retinopathy: A metaanalysis and systematic review. Int J Ophthalmol 2018; 11:287-295
128. Ang L, Jaiswal M, Martin C, Pop-Busui R. Glucose controland diabetic neuropathy: Lessons from recent large clinical trials. Curr Diab Rep 2014; 14:528
129. Martin CL, Albers JW, Pop-Busui R; DCCT/EDIC Research Group. Neuropathy and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care 2014; 37:31-38
130. Pop-Busui R, Boulton AJM, Feldman EL, et al. Diabetic neuropathy: A position statement by the American Diabetes Association. Diabetes Care 2017; 40:136-154
131. Freeman R. Not all neuropathy in diabetes is of diabetic etiology: Differential diagnosis of diabetic neuropathy. Curr Diab Rep 2009; 9:423-431
132. Pop-Busui R, Evans GW, Gerstein HC, et al.; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care 2010; 33:1578-1584
133. Pop-Busui R, Cleary PA, Braffett BH, et al.; DCCT/EDIC Research Group. Association between cardiovascular autonomic neuropathy and left ventricular dysfunction: DCCT/EDIC study (Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications). J Am Coll Cardiol 2013; 61:447-454
134. Smith AG, Lessard M, Reyna S, Doudova M, Singleton JR. The diagnostic utility of Sudoscan for distal symmetric peripheral neuropathy. J Diabetes Complications 2014; 28:511-516
135. Diabetes Control and Complications Trial (DCCT) Research Group. Effect of intensive diabetes treatment on nerve conduction in the Diabetes Control and Complications Trial. Ann Neurol 1995; 38:869-880
136. CDC Study Group. The effect of intensive diabetes therapy on measures of autonomic nervous system function in the Diabetes Control and Complications Trial (DCCT). Diabetologia 1998; 41:416-423
137. Albers JW, Herman WH, Pop-Busui R, et al.; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of prior intensive insulin treatment during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications (EDIC) study. Diabetes Care 2010; 33:1090-1096
138. Pop-Busui R, Low PA, Waberski BH, et al.; DCCT/EDIC Research Group. Effects of prior intensive insulin therapy on cardiac autonomic nervous system function in type 1 diabetes mellitus: The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study (DCCT/EDIC). Circulation 2009; 119:2886-2893
139. Callaghan BC, Little AA, FeldmanEL, Hughes RAC. Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database Syst Rev 2012; 6:CD007543
140. Pop-Busui R, Lu J, Brooks MM, et al.; BARI 2D Study Group. Impact of glycemic control strategies on the progression of diabetic peripheral neuropathy in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Cohort. Diabetes Care 2013; 36:3208-3215
141. Sadosky A, Schaefer C, Mann R, et al. Burden of illness associated with painful diabetic peripheral neuropathy among adults seeking treatment in the US: Results from a retrospective chart review and cross-sectional survey. Diabetes Metab Syndr Obes 2013; 6:79-92
142. Waldfogel JM, Nesbit SA, Dy SM, et al. Pharmacotherapy for diabetic peripheral neuropathy pain and quality of life: A systematic review. Neurology 2017; 88:1958-1967
143. Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: A systematic review and meta-analysis. Lancet Neurol 2015; 14:162-173
144. Bril V, England J, Franklin GM, et al.; American Academy of Neurology; American Association of Neuromuscular and Electrodiagnostic Medicine; American Academy of Physical Medicine and Rehabilitation. Evidence-based guideline: Treatment of painful diabetic neuropathy: Report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation [published correction appears in Neurology 2011; 77:603]. Neurology 2011; 76: 1758-1765
145. Griebeler ML, Morey-Vargas OL, Brito JP, et al. Pharmacologic interventions for painful diabetic neuropathy: An umbrella systematic review and comparative effectiveness network meta-analysis. Ann InternMed 2014; 161:639-649
146. Ziegler D, Fonseca V. From guideline to patient: A review of recent recommendations for pharmacotherapy of painful diabetic neuropathy. J Diabetes Complications 2015; 29: 146-156
147. Freeman R, Durso-Decruz E, Emir B. Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: Findings from seven randomized, controlled trials across a range of doses. Diabetes Care 2008; 31: 1448-1454
148. Moore RA, Straube S, Wiffen PJ, Derry S, McQuayHJ. Pregabalin for acute andchronic pain in adults. Cochrane Database Syst Rev 2009 (3): CD007076
149. Raskin P, HuffmanC, TothC, et al. Pregabalin in patients with inadequately treated painful diabetic peripheral neuropathy: A randomizedwithdrawal trial. Clin J Pain 2014; 30:379-390
150. Tesfaye S, Wilhelm S, Lledo A, et al. Duloxetine and pregabalin: High-dose monotherapy or their combination? The "COMBO-DN study"-a multinational, randomized, double-blind, parallelgroup study in patients with diabetic peripheral neuropathic pain. Pain 2013; 154:2616-2625
151. Ziegler D, Duan WR, An G, Thomas JW, NothaftW. A randomized double-blind, placebo-, and active-controlled study of T-type calcium channel blocker ABT-639 in patients with diabetic peripheralneuropathicpain. Pain 2015; 156:2013-2020
152. Quilici S, Chancellor J, Löthgren M, et al. Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain. BMC Neurol 2009; 9:6
153. Dworkin RH, Jensen MP, Gammaitoni AR, Olaleye DO, Galer BS. Symptom profiles differ in patients with neuropathic versus nonneuropathic pain. J Pain 2007; 8:118-126
154. Wiffen PJ, Derry S, Bell RF, et al. Gabapentin for chronic neuropathic pain in adults. Cochrane Database Syst Rev 2017; 6:CD007938
155. Wernicke JF, Pritchett YL, D'Souza DN, et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology 2006; 67:1411-1420
156. Hardy T, Sachson R, Shen S, Armbruster M, Boulton AJM. Does treatment with duloxetine for neuropathic pain impact glycemic control? Diabetes Care 2007; 30:21-26
157. Schwartz S, Etropolski M, Shapiro DY, et al. Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: Results of a randomized-withdrawal, placebo-controlled trial. CurrMed Res Opin 2011; 27:151-162
158. Vinik AI, Shapiro DY, Rauschkolb C, et al. A randomized withdrawal, placebo-controlled study evaluating the efficacy and tolerability of tapentadol extended release in patients with chronic painful diabetic peripheral neuropathy. Diabetes Care 2014; 37:2302-2309
159. Briasoulis A, Silver A, Yano Y, Bakris GL. Orthostatic hypotension associated with baroreceptor dysfunction: Treatment approaches. J Clin Hypertens (Greenwich) 2014; 16:141-148
160. Figueroa JJ, Basford JR, Low PA. Preventing and treating orthostatic hypotension: As easy as A, B, C. Cleve Clin J Med 2010; 77:298-306
161. Jordan J, Fanciulli A, Tank J, et al. Management of supine hypertension in patients with neurogenic orthostatic hypotension: Scientific statement of the American Autonomic Society, European Federation of Autonomic Societies, and the European Society of Hypertension. J Hypertens 2019; 37:1541-1546
162. CamilleriM, ParkmanHP, ShafiMA, Abell TL, Gerson L; American College of Gastroenterology. Clinical guideline: Management of gastroparesis. Am J Gastroenterol 2013; 108:18-37
163. Parrish CR, Pastors JG. Nutritional management of gastroparesis in people with diabetes. Diabetes Spectr 2007; 20:231-234
164. Parkman HP, Yates KP, Hasler WL, et al.; NIDDK Gastroparesis Clinical Research Consortium. Dietary intake and nutritional deficiencies in patients with diabetic or idiopathic gastroparesis. Gastroenterology 2011; 141:486-498, 498.e1-498.e7
165. Olausson EA, Störsrud S, Grundin H, Isaksson M, Attvall S, Simrén M. A small particle size diet reduces upper gastrointestinal symptoms in patients with diabetic gastroparesis: Arandomized controlled trial. AmJ Gastroenterol 2014; 109:375-385
166. Umpierrez GE, Ed. Therapy for Diabetes Mellitus andRelatedDisorders. 6thed. Alexandria, VA, American Diabetes Association, 2014
167. Sugumar A, Singh A, Pasricha PJ. A systematic review of the efficacy of domperidone for the treatment of diabetic gastroparesis. Clin Gastroenterol Hepatol 2008; 6:726-733
168. Maganti K, Onyemere K, Jones MP. Oral erythromycin and symptomatic relief of gastroparesis: A systematic review. Am J Gastroenterol 2003; 98:259-263
169. McCallum RW, Snape W, Brody F, Wo J, Parkman HP, Nowak T. Gastric electrical stimulation with Enterra therapy improves symptoms fromdiabetic gastroparesis in a prospective study. Clin Gastroenterol Hepatol 2010; 8:947-954
170. Bus SA, van Deursen RW, Armstrong DG, Lewis JE, Caravaggi CF, Cavanagh PR; International Working Group on the Diabetic Foot. Footwear and offloading interventions to prevent and heal foot ulcers and reduce plantar pressure in patients with diabetes: A systematic review. Diabetes Metab Res Rev 2016; 32(Suppl. 1):99-118
171. Ulbrecht JS, Hurley T, Mauger DT, Cavanaugh PR. Prevention of recurrent foot ulcers with plantar pressure-based in-shoe orthoses: The CareFUL Prevention multicenter randomized controlled trial. Diabetes Care 2014; 37:1982-1989
172. BoultonAJM, ArmstrongDG, Albert SF, et al.; American Diabetes Association; American Association of Clinical Endocrinologists. Comprehensive foot examination and risk assessment: A report of the task force of the foot care interest group of the AmericanDiabetesAssociation, withendorsement by the American Association of Clinical Endocrinologists. Diabetes Care 2008; 31:1679-1685
173. Hingorani A, LaMuraglia GM, Henke P, et al. The management of diabetic foot: A clinical practiceguidelineby the Society forVascularSurgery in collaborationwiththeAmerican PodiatricMedical Association and the Society for VascularMedicine. J Vasc Surg 2016; 63(Suppl.):3S-21S
174. Litzelman DK, Slemenda CW, Langefeld CD, et al. Reduction of lower extremity clinical abnormalities in patients with non-insulindependent diabetes mellitus. A randomized, controlled trial. Ann Intern Med 1993; 119:36-41
175. IWGDF. IWGDF Guidelines on the prevention and management of diabetic foot disease.Accessed 12 September 2019.Available from https://iwgdfguidelines.org/wp-content/uploads/2019/05/IWGDF-Guidelines-2019.pdf
176. Bonner T, Foster M, Spears-Lanoix E. Type 2 diabetes-related foot care knowledge and foot self-care practice interventions in the United States: A systematic review of the literature. Diabet Foot Ankle 2016; 7:29758
177. Lipsky BA, Berendt AR, Cornia PB, et al.; Infectious Diseases Society of America. 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Clin Infect Dis 2012; 54:e132-e173
178. Elraiyah T, Tsapas A, Prutsky G, et al. A systematic review and meta-analysis of adjunctive therapies in diabetic foot ulcers. J Vasc Surg 2016; 63(2 Suppl.):46S-58S.e1-2
179. Game FL, Apelqvist J, Attinger C, et al.; International Working Group on the Diabetic Foot. Effectiveness of interventions to enhance healing of chronic ulcers of the foot in diabetes: A systematic review. Diabetes Metab Res Rev 2016; 32(Suppl. 1):154-168
180. Kranke P, Bennett MH, Martyn-St James M, Schnabel A, Debus SE, Weibel S. Hyperbaric oxygen therapy for chronic wounds. Cochrane Database Syst Rev 20156:CD004123
181. Löndahl M, Katzman P, Nilsson A, Hammarlund C. Hyperbaric oxygen therapy facilitates healing of chronic foot ulcers in patients with diabetes. Diabetes Care 2010; 33: 998-1003
182. Fedorko L, Bowen JM, Jones W, et al. Hyperbaric oxygen therapy does not reduce indications for amputation in patients with diabetes with nonhealing ulcers of the lower limb: A prospective, double-blind, randomized controlled clinical trial. Diabetes Care 2016; 39: 392-399
183. Li G, Hopkins RB, Levine MAH, et al. Relationship between hyperbaric oxygen therapy and quality of life in participants with chronic diabetic foot ulcers: Data from a randomized controlled trial. Acta Diabetol 2017; 54:823-831
184. Boulton AJM. The Diabetic Foot, 2000. South Dartmouth, MA, MDText.com, Inc.Accessed 4 November 2019. Available from http://www.ncbi.nlm.nih.gov/books/NBK409609/
185. Hyperbaric Oxygen Therapy for the Treatment of Diabetic Foot Ulcers. A health technology assessment. Ont Health Technol Assess Ser 2017; 17:1-142
186. Stoekenbroek RM, Santema TB, Koelemay MJ, et al. Is additional hyperbaric oxygen therapy cost-effective for treating ischemic diabetic ulcers? Study protocol for the Dutch DAMOCLES multicenter randomized clinical trial. J Diabetes 2015; 7:125-132
187. Huang ET, Mansouri J, Murad MH, et al.; UHMS CPG Oversight Committee. A clinical practice guideline for the use of hyperbaric oxygen therapy in the treatment of diabetic foot ulcers. Undersea Hyperb Med 2015; 42: 205-247
188. Vassalotti JA, Centor R, Turner BJ, Greer RC, Choi M, Sequist TD; National Kidney Foundation Kidney Disease Outcomes Quality Initiative. Practical approach to detection and management of chronic kidney disease for the primary care clinician. Am J Med 2016; 129:153-162.e7